Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Progress has been made recently in developing antibody-drug conjugates (ADCs) that can
selectively deliver cancer drugs to tumor cells. In principle, the idea is simple: by attaching …

An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer
cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with …

The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …

CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized
over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston …

Treatment of B-cell non-Hodgkin's lymphoma has become more successful, largely owing to
the availability of therapeutic monoclonal antibodies, which may avoid the toxic effects of …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …

The development of new bio-orthogonal ligation methods for the conjugation of native
proteins is of particular importance in the field of chemical biology and biotherapies. In this …

The pathogenic roles of B cells in autoimmune diseases occur through several mechanistic
pathways that include autoantibodies, immune complexes, dendritic and T cell activation …

Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in adults,
with B-cell lymphomas accounting for 85% of all NHLs. The most substantial advancement …